A Clinical Study Of S-1 In The Treatment Of Advanced Gastric Cancer

Objective: 1. To observe the effectiveness and safety of a combination therapy of S-1 and Oxaliplatin in the treatment of advanced gastric cancer,compared with a chemotherapy regimen of tegafur and Oxaliplatin.2.To analyze the effectiveness and safety of the S-1 single- agent therapy for advanced gastric cancer which had been treated by Oxaliplatin.Method: 1. 44 advanced gastric cancer patients were randomly divided into trial group and control group.S-1 was administered orally twice daily in the trail group ,at a standard dose of 80 mg/m~2 per day for 14 consecutive days, followed by a 14-day rest period and intravenous of Oxaliplatin(130mg/m~2) was administered on day 1 of every 4 week. While in the control group, FT(800 mg/m~2 ) was administered orally twice daily for 14 consecutive days, followed by a 14 day rest period and intravenous of Oxaliplatin(130mg/m~2) was administered on day 1 of every 4 week .This period was defined as one course of treatment. The effectiveness and safety were estimated after two courses of treatment. 2. 6 advanced gastric cancer patients who had been treated by Oxaliplatin were eligible for the single-agent group.S-1 were administrated orally twice daily ,at a standard dose of 80 mg/m~2 per day for 28 consecutive days, followed by a 14-day rest period, This period was defined as one course of treatment. The effectiveness and safety were estimated after two course of treatment.Results: 1. There were 22 advanced gastric cancer patients in the trial group and control group respectively. In the trial group, 1 patient only finished the...